- Published date :
-
Apr 27, 2010
- Expired date :
-
Apr 27, 2040
April 27, 2010 – Wilmington, DE – AstraZeneca announced today that the company has finalized a previously announced agreement in principle with federal and state entities in the United States to resolve civil allegations relating to the company’s past marketing and promotion of its atypical antipsychotic, SEROQUEL.
The final agreement is with the United States Attorney’s Office for the Eastern District of Pennsylvania, the United States Department of Justice, various other federal agencies, the National Association of Medicaid Fraud Control Units (NAMFCU) and the two qui tam relators.
Under the terms of the agreement, AstraZeneca denies the allegations but will pay a previously disclosed $520 million that was taken as a reserve in 2009, along with certain accrued interest. A portion of the payment will be distributed to states participating in the NAMFCU settlement.
As part of the settlement, AstraZeneca has entered into a corporate integrity agreement with the Office of Inspector General of the United States Department of Health and Human Services. The corporate integrity agreement will be in effect for five years.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of $32.8 billion in 2009. In the United States, AstraZeneca is a $14.8 billion healthcare business.
For more information about AstraZeneca in the US or our AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).
Media Contacts:
- Tony Jewell, AstraZeneca (US): 302-885-4594
- Neil McCrae, AstraZeneca (UK): +44 20 7304 5045
- Chris Sampson, AstraZeneca (UK): +44 20 7304 5130
- Sarah Lindgreen, AstraZeneca (UK): +44 20 7304 5033
- Abigail Baron, AstraZeneca (UK): +44 20 7304 5034
Investor Enquiries:
- Jonathan Hunt, AstraZeneca (UK): +44 207 304 5087
- Karl Hård, AstraZeneca (UK): +44 207 304 5322
- Clive Morris, AstraZeneca (UK): +44 207 304 5084
- Ed Seage, AstraZeneca (US): 302-886-4065
- Jorgen Winroth, AstraZeneca (US): 212-579-0506
